---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063702"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:21:20.262197+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics raises FY2023 oncology sales guidance; projects FY2024 EBITDA breakeven

## Summary
- FY2023 net product sales guidance raised to $123-125M; oncology franchise now $104-106M.
- FY2024 net product sales expected $138-158M; acute care franchise growing >48% YoY.
- Gross margin forecast to improve from 41% (2023) to 69% (2024) and >75% (2025+).
- Q3 2023 inventory write-offs of $7.5M; one-time expenses $4.1M; loss from ops $24.9M.
- ZYNRELEF expanded label PDUFA date Jan 23, 2024; VAN program PAS submission early 2024.

## SEC filing metadata
- accession: 0000950170-23-063702
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023063702/0000950170-23-063702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023063702/hrtx-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063702
- JSON: https://secwatch.observer/filing/0000950170-23-063702.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063702.txt

## Key facts
- Earnings Releases
  HERON THERAPEUTICS, INC. /DE/ updated its three and nine months ended September 30, 2023 guidance (raised).
  - Period: three and nine months ended September 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: On November 14, 2023, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023 (“Earnings Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023063702/0000950170-23-063702-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.